Posted On: 10/28/2015 11:12:29 PM
Post# of 72445
AVXL was a zombie stock for a few years until it's recent pump that made me curious. Before that, circa 2009, Anavex was hyped as a great drug for Alzheimer's disease by newsletter writer like Patrick Cox (formerly write for "Breakthrough Technology Alert"
.
Back then, a guy named Cameron Durrant was hired as a CEO. He was formerly a J&J executive, seemingly to indicate a validation. The flagship drug Anavex 2-73 started to go into Phase 1 studies in 2011 and it sounds promising enough until sometime in late 2011, this Durrant guy suddenly resigned .
Since then the company has been changing it's CEO (until I don't know how many CEO has been taking helm so far) and the stock continued its decline until early 2015?
And there has been no new approved Alzheimer's drug for quite a very long time- the recent drug failure was back in 2012 when Eli Lily's solanezumab failed its P2 studies and Australia-based Prana Biotech's PBT2 failed in P2 studies as well. It has been failure upon failure for Alzheimer's disease drug .
. Back then, a guy named Cameron Durrant was hired as a CEO. He was formerly a J&J executive, seemingly to indicate a validation. The flagship drug Anavex 2-73 started to go into Phase 1 studies in 2011 and it sounds promising enough until sometime in late 2011, this Durrant guy suddenly resigned .
Since then the company has been changing it's CEO (until I don't know how many CEO has been taking helm so far) and the stock continued its decline until early 2015?
And there has been no new approved Alzheimer's drug for quite a very long time- the recent drug failure was back in 2012 when Eli Lily's solanezumab failed its P2 studies and Australia-based Prana Biotech's PBT2 failed in P2 studies as well. It has been failure upon failure for Alzheimer's disease drug .
(0)
(0)
